Review

Use of graphene-based materials as carriers of bioactive agents

Wing-Fu Laia,b,*, Wing-Tak Wongb

a Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, The Chinese University of Hong Kong (Shenzhen), Shenzhen 518172, China
b Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong, Special Administrative Region, China

ARTICLE INFO

Article history:
Received 22 June 2020
Revised 1 October 2020
Accepted 10 November 2020
Available online 7 December 2020

Keywords:
Graphene
Carbon
Nanomaterial
Loading
Controlled release

ABSTRACT

Graphene possesses a large specific surface area, a high Young's modulus, high fracture strength, high electrical conductivity, and excellent optical performance. It has been widely studied for biomedical use since its first appearance in the literature. This article offers an overview of the latest advances in the design of graphene-based materials for delivery of bioactive agents. To enhance the translation of these carriers into practical use, the toxicity involved is needed to be examined in future research in more detail. In addition, guidelines for standardizing experimental conditions during the evaluation of the performance of graphene-based materials are required to be established so that candidates showing higher practical potential can be more effectively identified for further development. This can streamline the optimization and use of graphene-based materials in delivery applications. © 2021 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Carbon is a group IV element. It exists in multiple forms (including graphite, fullerene, diamond, and amorphous carbon) [1]. Although each crystalline form of carbon has its unique physical properties, all crystalline forms possess a common 2D structure, namely graphene, which is a single layer of sp²-hybridized carbon atoms arranged in a honeycomb crystal lattice. In graphene, each carbon atom is connected to three carbon atoms, with the C-C bond length and the bond angle being around 1.42 Å and 120° [2], respectively. Because the carbon skeleton of graphene consists of σ-bonds with paired electron clouds above and below the skeleton, this bonding system is similar to that observed in benzene. Graphene is, therefore, regarded as a polycyclic aromatic hydrocarbon.

Graphene has been widely studied for biomedical use since its first appearance in 2004 [3], partly owing to its high Young's modulus, high fracture strength, high electrical conductivity, and excellent optical performance. Graphene also possesses a large specific surface area for adsorption of bioactive compounds and has high optical absorption...
efficiency in the near-infrared (NIR) region. Compared to other types of carriers (such as polymeric nanoparticles [4,5], hydrogels [6–9], and liposomes [10,11]) which display very few functionalities, if any, unless further manipulation is performed, graphene-based carriers intrinsically enable not only delivery of bioactive agents but also the execution of physical treatments such as photodynamic therapy [12,13]. On the other hand, compared to metal particles which are deficient of functional groups for direct functionalization [14,15], graphene-based materials possess a large number of reactive groups for chemical modification, enabling more precise optimization of chemical properties as carriers. The unique properties of graphene as mentioned above render graphene and its related materials attractive in delivery research.

2. Generation and use of graphene-based carriers for agent loading

Graphene can be generated by using multiple methods (Fig. 1), including mechanical exfoliation [16], oxidative exfoliation-reduction [17], arc discharge [18], total organic synthesis [19], liquid-phase exfoliation [20], template routes [21], epitaxial growth [22], substrate-free gas-phase synthesis [23], and chemical vapor deposition (CVD) [24]. Because 2D graphene can be manipulated to form 0D structures [e.g., fullerenes and graphene quantum dots (GQDs)], rolled into 1D structures (e.g., carbon nanoribbons and nanotubes), or stacked into 3D structures (e.g., graphite), it is the building block of carbon-based materials with diverse dimensions. Upon the generation of graphene, graphene oxide (GO) can be obtained by oxidizing carboxyl groups and hydroxyl groups on the graphene plane. Oxidation increases the solubility of graphene; however, due to van der Waals interactions between GO nanosheets, aggregation of the nanosheets easily occurs in the physiological environment. This partially accounts for the occurrence of toxic effects during biomedical use of GO.

To use graphene and its derivatives as carriers, the bioactive agent has to be first loaded into the materials. This can be achieved by first dispersing the agent in an aqueous GO dispersion, followed by the addition of a reducing agent [25]. Compared to pristine graphene, more active groups are available on the surface of GO. These active groups cannot only provide sites for covalent binding of the agent to the GO surface, but also allow for structural modification of GO. The latter is exemplified by the success of modifying the GO surface with polyethylene glycol (PEG) and poly(ethyleneimine) (PEI) via nucleophilic substitution, generating nanocarriers showing high dispersibility for bioactive agent delivery [26,27]. Apart from the covalent means, non-covalent interactions can be adopted to load various agents into graphene-based materials and to manipulate the properties of GO. For example, due to the availability of carboxyl groups, polyelectrolytes can be adsorbed on the GO surface via electrostatic forces [28]. Through physisorption, doxorubicin (DOX) has also been loaded into gelatin-functionalized graphene nanosheets for delivery purposes [29]. More recently, chitosan-functionalized GO has been used as a carrier of ibuprofen and 5-fluorouracil [30]. The drug loading process is mediated largely by π–π stacking and hydrophobic interactions. The adoption of such non-covalent interactions, indeed, can prevent changing or destroying the intrinsic structure and physical properties of the loaded agent.

3. Methods of manipulating the properties of graphene-based carriers

Manipulation of the physicochemical properties of graphene-based carriers can modify the pharmacokinetic profile achieved [31,32]. Because graphene is the building block of 0D, 1D and 3D structures, manipulating the size and shape of graphene-based nanosheets may help control the size and shape of the derived carriers.

3.1. Size manipulation

Size is one of the important factors affecting the performance of a carrier [6,33–35]. In general, carriers having a size of 5 nm or less are easily excreted from the body in urine [36]. Those having a larger size may tend to accumulate in the heart [37], bone marrow [38], kidney [39,40], stomach [41], spleen [42], and liver [43]. To manipulate the size of a graphene-based nanosheet (and hence the size of the carrier derived), one of the simplest approaches is to use the separation method, which has previously been used to obtain ultrasmall nano-graphene oxide (NGO) [44]. Generation of NGO begins with the activation of GO using chloroacetic acid to produce GO–COOH, which is subsequently grafted with 6-arm branched PEG molecules and finally undergoes density gradient ultracentrifugation to obtain the product [26,44]. Apart from using density gradient ultracentrifugation, GO with different dimensions can be separated based on pH-dependent amphiphilicity [45,46]. This method provides a facile strategy to control the size distribution of graphene-based nanosheets for subsequent carrier fabrication.

Graphene-based nanosheets can be etched to specific dimensions directly by using electron-beam lithography, local
electrochemical etching, reactive plasma etching, and O\textsubscript{2} plasma etching with templates, too [47–49]. The use of these methods in large-scale production of graphene-based carriers is, however, limited due to the high production cost. This problem may be alleviated by the emergence of the solution-based cutting approach [50], which has been reported to generate a 0D structure with an average diameter of 9.6 nm from GO. Another method to solve the problem involved in conventional etching is to control the process of bottom-up synthesis. The feasibility of this has been suggested by an earlier study [51], which has fabricated nano-sized N-doped GO by cutting and unzipping N-doped carbon nanotubes (CNTs). During synthesis, N-doped CNTs are first fabricated via CVD [51]. After that, acid treatment is performed to generate nano-sized N-doped GO. The size and thickness of the product are negatively related to the length of the oxidation time [51], and hence can be manipulated by controlling reaction conditions.

3.2. Shape manipulation

The shape of the graphene-based nanosheet is another parameter to be considered during the fabrication and optimization of a graphene-based carrier because it may ultimately affect the kinetics of diffusional mass transport of the loaded agent [52,53], cellular uptake efficiency [54,55], and blood retention time [54,55]. Graphene-based nanosheets with different shapes can be made by nanocutting [56], in which nickel nanoparticles are adopted as a knife to cut nanosheets with high precision. Via methane CVD on a copper surface, equiangular hexagon-shaped graphene flakes with either an armchair edge or a zigzag edge can also be produced [57]. Along with the success of obtaining both single-layered and multi-layered graphene flakes [57], the possibility of engineering the shape of graphene-based carriers has been enhanced.

More recently, circular and elliptical GQDs have been successfully produced by using GO nanosheets [58]. During synthesis, GO nanosheets are first generated from graphite powder, followed by deoxygenation at 250 °C to produce reduced GO (rGO) powder. After oxidation of the powder in an acidic environment, the acid is removed. Purified GO powder is subjected to heating at 250 °C and is dispersed in distilled water to form a suspension, which is filtered through a nanoporous membrane to obtain a brown solution in which GQDs are present. The shape of the GQDs has been found to link with the size (Fig. 2) [58]. When the GQDs have a diameter of around 5–10 nm, they are largely circular and elliptical in shape. When the diameter is increased to 15 nm, mainly elliptical GQDs are found. When the diameter reaches 20 nm, most of the GQDs are hexagon-shaped, with around 25% of them deformed with curved sides. At the diameter of 35 nm, GQDs take the form of parallelogram-type rectangles with rounded vertices. Although this method of shape manipulation can only be applied to GQD production, it provides a route to easily fabricate graphene-based carriers with diverse shapes when GQDs are adopted as the starting material.

4. Roles of graphene-based materials in bioactive agent delivery

As far as the use of graphene-based materials in agent delivery is concerned, one of the major uses is to apply the materials as modifiers to enhance the delivery performance of other carriers. The feasibility of this has been demonstrated by Chen and coworkers [59], who have fabricated dissolvable microneedles for transdermal drug delivery. In fact, polymeric microneedles are one of the most extensively used systems for transdermal drug administration because of their minimal invasiveness that can lead to high patient compliance [59]. Upon GO incorporation, the microneedles display not only improved mechanical strength and higher moisture resistance [59], but also antibacterial and anti-inflammatory properties in the in vitro context [59]. Importantly, the presence of GO enables the microneedles to mediate near-infrared (NIR) light-activated controlled drug release [59]. This demonstrates the potential use of graphene-based materials as enhancers of other delivery systems. Such potential has been further corroborated by Aderibigbe and coworkers [60], who have generated a hydrogel biocomposite from gelation of a mixture containing acrylamide, N,N’-methylenebisacrylamide, N,N,N’,N’-tetramethylthelylenediamine, and potassium persulfate, with rGO serving as a modifier. Compared to the blank gel, the one containing rGO has shown higher release sustainability, and has displayed pH-responsiveness. This evidences the capacity of rGO to modify the hydrogel properties and hence the release pattern of the loaded agent.

Besides serving as a carrier modifier, graphene-based materials can function as carriers of bioactive agents per se. The mechanism undertaken by graphene-based carriers in
tegafur delivery has been investigated by an earlier study [61], which has performed molecular dynamics simulation to elucidate how tegafur is delivered into cells by using GO nanosheets. At the start of the simulation, the tegafur-GO complex is located at a distance of about 2 nm from the model membrane. During the delivery process, the complex moves from the bulk water region to the 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) bilayer surface, with the nanosheet positioned almost vertically out of the membrane at the first 5 ns [61]. GO loses a part of its electrostatic interaction energy with the solvent due to its positioning on the plasma membrane; however, the amount of energy loss with water is compensated by the interaction energy of GO with POPC [61]. The complex subsequently touches the surface of the phospholipid bilayer. This is accompanied by a rapid decrease in both the electrostatic and van der Waals interaction energies of GO with the model membrane [61]. The tegafur-GO complex fluctuates in the vicinity of the membrane surface until the electrostatic and van der Waals interaction energies get their first minimum values [61]. At that time, hydrogen bonds are formed between GO and POPC [61]. Formation of these hydrogen bonds can prevent GO from moving far away from the membrane. When GO is inserted partially from water into the membrane, it enhances the membrane permeability of the loaded drug [61], partly because of the high affinity of tegafur to GO during the cellular internalization process and hence the minimal loss of the drug via drug release or passive diffusion.

Apart from tegafur, other compounds have been adopted as models to elucidate the interactions between the payload and graphene-based carriers during bioactive agent delivery. One of these is DOX. Molecular dynamics simulation reveals that the strength of the interactions between DOX and a graphene-based carrier is affected by the oxygen density on the graphene surface and by the pH of the surrounding medium [62]. In particular, DOX can interact strongly with the surface of pristine graphene via van der Waals interactions due to the π–π stacking of the aromatic group of the drug with the graphene surface [62]. A similar observation has also been made in the case of paclitaxel [63], which spontaneously moves towards the carrier and forms strong π–π interactions with the graphene surface (Fig. 3). Such interactions, however, may be changed upon surface modification of graphene. In particular, if the number of oxygen-containing functional groups on the graphene surface increases, electrostatic interactions will build up between the drug and the graphene surface while van der Waals interactions will be weakened [62]. By using GO with an O/C ratio of around 0.17 as a model for molecular dynamics simulation, the interaction energy of the DOX/GO system has been found to increase as the pH of the surrounding medium changes from 7 to 5 [62]. This suggests that drug molecules are more loosely adhered to the carrier surface, leading to an increase in the release rate. Such computational simulation of the processes of agent loading and release may streamline the design and engineering of graphene-based materials as carriers.

Fig. 3 – Close snapshots of (A, C) DOX and (B, D) paclitaxel interacting with the (A, B) graphene surface and the (C, D) GO surface. Reproduced from [63] with permission from Elsevier B.V.
5. Design of graphene-based materials for bioactive agent delivery

Owing to the capacity of graphene and its derivatives in enhancing membrane permeability of bioactive agents [61,62], over the years diverse carriers have been generated by using graphene as a building block (Table 1) [25,26,28,64–77]. The emergence of these carriers has not only made effective delivery of small molecules and biomacromolecules possible, but has also enabled co-delivery of multiple agents.

5.1. Delivery of small molecule compounds

During delivery of small molecule compounds, carriers have to interact with the plasma membrane and undergo cellular internalization via endocytosis. Release of the loaded compounds in the cytosolic compartment can be enhanced partly by taking advantage of the pH-responsiveness of some graphene-based carriers. One example of these carriers is the DOX-GO-chitosan-folic acid nanohybrid composite, which enables the release rate of DOX attained at acidic pH (5.3) much higher than that at physiological pH (7.4) [78]. Another example is the GO-based polyelectrolyte nanocomposite [74]. During synthesis, folic acid is first conjugated to chitosan via N,N-dicyclohexylcarbodiimide coupling [74]. After that, ethylene glycol dimethacrylate is adopted as a cross-linker to graft itaconic acid and acrylic acid to the chitosan backbone, followed by the use of potassium persulfate as an initiator to generate carboxyl groups to form chemically modified chitosan [74]. Upon mixing with amine-functionalized GO, the derivative of chitosan forms a nanocomposite, which can be loaded with DOX via π-π stacking interactions [74]. The loading capacity of the nanocomposite has been found to be as high as 95.0%, with the release rate of the loaded drug at pH 5.3 being substantially higher than that at physiological pH [74]. Apart from the pH-responsive carriers mentioned above, graphene-based carriers have been designed to respond to other stimuli. For instance, by functionalizing graphene sheets with poly(N-isopropylacrylamide), thermosensitive properties have been observed [79]. By linking a detachable FEG shell to NGO via disulfide linkages, redox-responsive drug release has also been achieved [80]. The rate of drug release has been found to be 2-fold higher upon intracellular glutathione (GSH) stimulation [80]. This demonstrates the technical feasibility of controlling the rate and onset of release of the loaded agent by rendering the graphene-based carrier stimuli-responsive via careful structural design.

To enhance the functionality of graphene-based carriers, few studies have incorporated the carriers with metal nanoparticles, too. One example is the hybrid consisting of GO and iron oxide (Fe3O4) nanoparticles. The hybrid is generated via wet chemical precipitation [81]. It can be uniformly dispersed in an aqueous solution before and after DOX loading, but undergoes agglomeration in an acidic environment. This pH-triggered behavior enables controlled release of the loaded agent. Another example is the Fe3O4/graphene composite (Fig. 4) [82]. Due to the presence of iron oxide, the composite shows higher electrical conductivity as compared to pristine graphene, and displays pH-triggered release of rhodamine-B. More recently, a FEG bis(amine)-functionalized GO/iron oxide nanocomposite has been developed for delivery of methotrexate [83]. The nanocomposite has high blood compatibility, and enables sustained drug release [83]. Although the role played by the superparamagnetic properties of the nanocomposite in controlling the release pattern of the loaded drug has not yet been extensively exploited, the possibility granted by iron oxide to enable the separation of the nanocomposite from the reaction mixture in the presence of an external magnetic field may facilitate the collection of the nanocomposite upon agent loading.
Table 1 – Examples of graphene-based materials of different dimensions reported for delivery of bioactive agents.

| Dimension | Type   | Agent          | Examples                                                                                                                                                                                                 | Ref. |
|-----------|--------|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 0D        | Fullerenes | Docetaxel      | C_{60}-fullerenes have been carboxylated, acylated and conjugated with docetaxel. They have successfully enhanced the bioavailability of docetaxel by 4.2 times and have decreased the rate of drug clearance by 50%. | [64] |
|           |        | Methotrexate    | C_{60}-fullerenes have been hydroxylated, followed by conjugation with methotrexate via a serum-stable and intracellularly hydrolysable ester bond. The system generated has effectively delivered methotrexate to cancer cells and has sustained the effective plasma concentration of methotrexate in vivo. | [65] |
| Quantum   | DOX    | Cyclic RGD-modified and DOX-loaded GQDs have been fabricated for chemo-photothermal combination therapy. | [66] |
| dots      |        | Enzalutamide    | Enzalutamide-loaded aminated GQDs have been functionalized with a tumor-targeting peptide and PEG for castration-resistant prostate cancer therapy. | [67] |
| Nucleic   | Methyl 3,3-dimethyl-2-(3-methyl-2,3-dihydrobenzofuran-2-yl)butanoate acid | The QGD has been linked covalently to the agent to be delivered by using a cleavage PEG linker. Riboflavin, which functions as a targeting ligand, has been incorporated into the QGD for targeted bioactive agent delivery. | [68] |
| 1D        | Nanotubes | Folic acid-conjugated CNTs have been loaded with irinotecan hydrochloride, and have enabled sustained release of the loaded drug. Folic acid-conjugated multi-walled CNTs have been used as a sustained-release carrier of cisplatin. It has shown high loading efficiency and high release sustainability, and has increased the efficiency in cellular uptake of cisplatin. | [70] |
| Nanoribbons | Ceramide | Oxidized graphene nanoribbons have been adopted as carriers to deliver long chain C_{35} and C_{44} ceramides to HeLa cells. | [71] |
|           | Lucanthone | Oxidized graphene nanoribbons have been coated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-aminopolyethylene glycol. The product formed has been loaded with lucanthone for delivery into tumor cells. | [72] |
| 2D        | GO      | Curcumin       | A nanocomposite hydrogel has been synthesized by using poly(vinyl alcohol) (PVA) and GO. The gel formed has been found to enhance colon targeting of curcumin and to increase the residence time of curcumin in the colon. | [73] |
| SN38      | NGO     | NGO has been functionalized with branched PEG. The product has been loaded with SN38 via π–π stacking for subsequent delivery purposes. | [74] |
| Nucleic   |        | Negatively charged GO has been processed with cationic PEI by electrostatic interactions. The stable complex formed has been used to further complex with a plasmid for transfection. | [75] |
| DOX       |        | GO has reacted with triethyl tetramine in the presence of 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The product formed has then been adopted to fabricate nanocomposites with chemically modified chitosan for delivery of DOX. | [76] |
| DOX and camptothecin | NGO has been functionalized with sulfonic acid groups and incorporated covalently with folic acid. The product formed has been loaded with DOX and camptothecin via π–π stacking and hydrophobic interactions. It has successfully delivered the payloads to MCF-7 cells. Graphite has been oxidized and incorporated into a PVA/poly(N-isopropylacrylamide) composite hydrogel. The presence of graphite oxide has facilitated heat transfer within the hydrogel matrix. Along with the presence of a micro-heater, the gel has been adopted for transdermal delivery of ketoprofen. | [77] |
| 3D        | Graphite | Ketoprofen      | A film consisting of graphite nanoplatelets and poly(l-lactide) has been adopted as a sustained-release carrier of THP. The presence of graphite nanoplatelets has conferred electrical conductivity to the film, thereby enabling the rate of THPP release to be tuned via manipulation of an electric field applied to the system. | [78] |
Table 2 – Major polymeric modifiers of graphene-based materials for delivery of nucleic acids.

| Polymer          | Examples                                                                 | Ref. |
|------------------|--------------------------------------------------------------------------|------|
| PEI              | GO has been functionalized with PEI, and has subsequently been adopted to deliver mRNA encoding the reprogramming factor (including Oct4, Sox2, Klf4, c-Myc) to adipose-derived fibroblasts. GO has been functionalized with PEI. The product has been reported to successfully deliver plasmids to H293T and U2O cells. Graphene nanoribbons have been functionalized with PEI for cellular delivery of the locked nucleic acid-modified molecular beacon for recognition of microRNA. GO has first undergone oleic acid adsorption, followed by functionalization with poly(amideamine) via covalent linkages between the amine groups of poly(amideamine) and the carboxyl groups of oleic acid. The product generated has successfully delivered plasmids into mammalian cells. GO has been functionalized with PEG prior to a reduction reaction. The product generated has been adopted as a carrier of single-stranded RNA. PEG has been incorporated into NGO for delivery of the molecular beacon into HeLa cells. GO has been incorporated with poly-L-lysine for delivery of Cpg oligodeoxynucleotides (ODNs) into murine Raw264.7 macrophages. PSS has been used, along with PEI, to functionalize GO via layer-by-layer self-assembly. The product generated has been adopted for co-delivery of adriamycin and miR-21-targeted siRNA. Atom transfer radical polymerization (ATRP) initiation sites containing disulfide bonds have first been incorporated into the surface of GO, followed by surface-initiated ATRP of 2-(dimethyl amino)ethyl methacrylate. The product generated has shown the capacity of gene/drug co-delivery. Nanocomposites have been generated by the self-assembly of GO and chitosan via electrostatic interactions. The nanocomposites have enabled effective delivery of Cpg ODNs into murine Raw264.7 macrophages. PepFect14 (PF14) and PepFect221 (PF221) have been conjugated to GO for delivery of plasmids, splice correction oligonucleotides, and siRNA. An octaarginine peptide has been conjugated to GO for delivery of plasmids into mammalian cells. |
| PEG              |                                                                         |      |
| Poly-L-lysine    |                                                                         |      |
| Poly(sodium 4-styrenesulfonates) (PSS) |                                                                         |      |
| Poly(2-(dimethyl amino)ethyl methacrylate) |                                                                         |      |
| Chitosan         |                                                                         |      |
| Peptides         |                                                                         |      |

5.2. Delivery of biomacromolecules

Graphene-based materials can carry not only small molecules but also proteins and peptides. In an earlier study, amine-terminated GO has been loaded with protein therapeutics (ribonuclease A and protein kinase A), and has been found to protect the therapeutics from enzymatic hydrolysis during the delivery process [84]. Bone morphogenetic protein-2 (BMP-2) has been loaded successfully onto a titanium substrate coated with layers of positively (GO-NH3+) and negatively (GO-COO−) charged GO nanosheets [85]. Apart from proteins and peptides, nucleic acids can be carried by graphene [86]. This is partly attributed to the interactions between graphene and nucleobases. Such interactions have been verified by Varghese and coworkers [87], who have performed isothermal titration calorimetry and have observed that the binding energy between graphene and guanine is the highest, followed by adenine, cytosine and thymine. Because graphene and its derivatives can protect DNA from enzymatic degradation [86,88], they show potential to function as non-viral carriers of nucleic acids. Despite this, contrary to single-stranded nucleic acids which can be easily loaded into graphene-based carriers via hydrophobic interactions and π-π stacking interactions [86], the efficiency in loading double-stranded DNA into graphene-based carriers is generally low because the nucleobases are hidden in the double-helix structure, thereby failing to form π-π stacking interactions with the carriers [89].

To enhance the efficiency in loading nucleic acids, graphene-based carriers are often functionalized with polycations. One of the widely used polycations is PEI [90], which on one hand can interact with negatively charged nucleic acids [91–95] and on the other hand can provide active groups for further functionalization to enhance the transfection efficiency and the tissue targeting capacity. This is demonstrated by an earlier study [96], which has functionalized GO with PEI as a gene carrier and has found that the PEI moieties enable the carrier to complex with nucleic acids and to promote the adhesion of the complex to the plasma membrane for enhanced cellular uptake [96]. By labeling the nucleic acids with TOTO-3 before complexation with PEI-functionalized GO, PC-3 cells transfected with the complex has exhibited green fluorescence under confocal fluorescence microscopy [90]. This provides a route to combine imaging with nucleic acid delivery (Fig. 5) [90].

Till now, PEI-functionalized graphene-based carriers have been widely adopted in gene therapy of diverse diseases including myocardial infarction [97], osteoporosis [28], and cancer [88]. Apart from PEI, other agents (e.g., dendrimers, chitosan, and peptides) have been adopted to modify graphene-based materials for enhanced transfection (Table 2) [88,99–109].
achieved by either DOX- or camptothecin-loaded GO. Another example demonstrating the possible use of graphene-based carriers in co-delivery of multiple agents is the chitosan-GO complex, which makes simultaneous delivery of camptothecin and nucleic acids possible [113]. Recently, transferrin-targeting hyperbranched poly(amidoamine)-functionalized GO has been adopted to co-deliver docetaxel and matrix metalloproteinase 9 (MMP-9) short hairpin RNA (shRNA) [114]. The carrier can deliver the agents to HNE-1 cells, and gives chemotherapeutic sensitization effects [114]. By combining drug/gene co-delivery, chemotherapeutic sensitization, and active targeting into one single platform, this carrier warrants further development for use in cancer treatment.

Apart from letting the co-delivered agents to be released from the carrier naturally, by making use of the photothermal effect of irradiated NIR, controlled release of the co-delivered agents can be achieved. This has been suggested by the case of PEG- and PEI-functionalized rGO, which has been used to deliver DOX [115]. Upon cellular internalization of the carrier, NIR irradiation has been applied to successfully trigger DOX release [115]. That carrier has also shown potential to enable photothermal control of the nucleic acid delivery process [116]. In PC3 and NIH/3T3 cells, no cytotoxicity from the carrier alone has been observed [116]. Upon NIR irradiation, the carrier has induced heat to facilitate endolysosomal escape, leading to enhanced transfection [116]. Despite the fact that at the moment studies directly demonstrating the success of photothermally controlled release of multiple co-delivered agents are lacking, the successful use of PEI-functionalized rGO in delivering, though separately, both small molecule compounds and nucleic acids has pointed to this possibility. Future efforts directing to verifying this will be of immense practical value.

6. Conclusions and outlook

Graphene-based materials have been rapidly developed in recent years and, as presented in sections above, have shown high practical potential in delivery of bioactive agents. Despite this, extensive future efforts to verify the biocompatibility of these materials will be needed if their use involves either direct contact with body tissues or injection into the blood circulation. Clarification of the metabolic fate and biodistribution profile upon injection of those graphene-based materials is also in dire need before the attainment of the US Food and Drug Administration (FDA)’s approval. The legitimacy of this need has been evidenced by the capacity of GO to alter cell morphology and to damage the plasma membrane to trigger apoptosis [117]. In macrophages, necrotic cell death elicited by GO is partly linked to the initiation of the toll-like receptor 4 (TLR4) signaling pathway [118]. In addition, graphene nanosheets have been found to induce cellular damage by increasing the levels of various cytokines and their corresponding soluble receptors, especially interleukin-33 [119]. In the *in vivo* context, graphene nanosheets have led to signs of thromboembolism, inflammation, and immune activation in mice upon intravenous administration [119]. In fact, the toxicity of graphene-based carriers can be affected

---

**5.3. Co-delivery of multiple agents**

While the "single molecule, single target, and single drug" strategy dominates for most of the 20th century [110], multi-drug therapy has attracted increasing interest partly owing to its potential to boost the therapeutic efficiency beyond that of mono-drug therapy [111,112]. The possibility of using graphene-based materials to mediate multi-drug therapy has been illustrated by an earlier study [75], in which GO has first been functionalized with sulfonic acid groups followed by conjugation with folic acid [75]. The resulting carrier enables co-delivery of DOX and camptothecin, with the toxicity achieved in MCF-7 cells much higher than that.

---

**Fig. 5** – (A) A schematic diagram depicting the route of synthesis of GO functionalized with PEI. Abbreviations: EDC, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride; NHS, N-hydroxysuccinimide. (B) Confocal fluorescence microscopic images of PC-3 cells treated with (a) PEI-functionalized GO alone, (b) complexes formed between GO and TOTO-3-labeled plasmids, (c) complexes formed between PEI-functionalized GO and TOTO-3-labeled plasmids, and (d) complexes formed between PEI and TOTO-3-labeled plasmids. Nuclei were stained with DAPI. Photoluminescence was observed under excitation using a 488 nm laser. Reproduced from [90] with permission from American Chemical Society.
by diverse factors. As shown by the case of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)]-wrapped oxidized graphene nanoribbons, graphene-based materials display different levels of toxicity in different cell lines in dose- and time-dependent manners [120]. The forms of graphene used may also affect the toxic effects attained. This is supported by the observation that, upon injection of various forms of graphene (including GO, aggregated graphene, and dispersed graphene) into the lungs of mice, severe lung injury has been noted only in those treated with GO. Those treated with aggregated and dispersed graphene have experienced no significant lung injury [121]. The safe use of graphene-based carriers, therefore, has to be evaluated in a case-by-case basis.

Apart from the need of proper toxicological evaluation, efforts should be directed to deciphering the interactions between GO and body cells, as well as the subsequent cellular response. This can facilitate the prediction and optimization of the performance of graphene-based carriers in cellular internalization [122]. In addition, partly due to the lack of standardization of experimental procedures (particularly in terms of the use of controls and testing methods), fair and direct comparison among data from different studies can hardly be made, leading to the difficulty of identifying more promising candidates, among a plethora of reported graphene-based materials, for bioactive agent delivery [123]. Solving this problem requires collaborative efforts among researchers in the field. Raising the awareness of the necessity of procedural standardization is, therefore, a challenge to be settled in the forthcoming decades.

**Conflicts of interest**

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

**Acknowledgments**

The authors acknowledge the financial support received from the Chinese University of Hong Kong, Shenzhen (PF01001421 and UD01001421), Natural Science Foundation of Guangdong Province (2018A030310485), and Research Grants Council of the Government of Hong Kong Special Administrative Region (C5012-15E).

**REFERENCES**

[1] Ren Z, Lan Y, Wang Y. Aligned carbon nanotubes. Berlin, Heidelberg: Springer; 2012.
[2] Zhang Q, Wu Z, Li N, Pu Y, Wang B, Zhang T, Tao J. Advanced review of graphene-based nanomaterials in drug delivery systems: synthesis, modification, toxicity and application. Mater Sci Eng C Mater Biol Appl 2017;77:1363–75.
[3] Geim AK, Novoselov KS. The rise of graphene. Nat Mater 2007;6(3):183–91.
[4] Lai WF, Wong WT. Design of polymeric gene carriers for effective intracellular delivery. Trends Biotechnol 2016;36(7):713–28.
[5] Lai WF, Green DW, Jung HS. Linear poly(ethyleneimine) cross-linked by methyl-α-cyclodextrin for gene delivery. Curr Gene Ther 2014;14(4):258–68.
[6] Lai WF, Shum HC. A stimuli-responsive nanoparticulate system using poly(ethyleneimine)-graft-polyaspartate for controlled protein release. Nanoscale 2016;8(1):517–28.
[7] Lai WF, Hu C, Deng G, Lui KH, Wang X, Tsai TH, Wang S, Wong WT. A biocompatible and easy-to-make polyelectrolyte dressing with tunable drug delivery properties for wound care. Int J Pharm 2019;566:101–10.
[8] Lai WF, Susha AS, Rogach AL. Multicompartment microgel beads for co-delivery of multiple drugs at individual release rates. ACS Appl Mater Interfaces 2018;10(1):871–80.
[9] Lai WF, Huang E, Lui KH. Alginote-based complex fibers with the Janus morphology for controlled release of co-delivered drugs. Asian J Pharm Sci 2020. doi:10.1016/j.ajps.2020.05.003.
[10] Lai WF, Tang R, Wong WT. Tonically croslinked complex gels loaded with oleic acid-containing vesicles for transdermal drug delivery. Pharmaceutics 2020;12(8):725.
[11] Lai WF, Wong WT, Rogach AL. Molecular design of layer-by-layer functionalized liposomes for oral drug delivery. ACS Appl Mater Interfaces 2020;12(39):43341–51.
[12] Tabish TA, Scotton CJ, Ferguson DCJ, Lin L, de Veen AV, Lowry S, et al. Biocompatibility and toxicity of graphene quantum dots for potential application in photodynamic therapy. Nanomedicine 2018;13(15):1923–37.
[13] Gazz A, Fusco I, Khan A, Bedognetti D, Zavar B, Vitale F, et al. Photodynamic therapy based on graphene and MXene in cancer theranostics. Front Bioeng Biotechnol 2019;7:295.
[14] Lai WF, Rogach AL, Wong WT. Molecular design of upconversion nanoparticles for gene delivery. Chem Sci 2017;8(11):7339–58.
[15] Lai WF, Wong WT, Rogach AL. Development of copper nanoclusters for in vitro and in vivo theranostic applications. Adv Mater 2020;32(9):e1906872.
[16] Novoselov KS, Geim AK, Morozov SV, Jiang D, Zhang Y, Dubonos SV, et al. Electric field effect in atomically thin carbon films. Science 2004;306(5696):666–9.
[17] Emiru TT, Ayele DW. Controlled synthesis, characterization and reduction of graphene oxide: a convenient method for large scale production. Egyptian J Basic Appl Sci 2017;4(1):74–9.
[18] Wu XH, Liu Y, Yang H, Shi ZJ. Large-scale synthesis of high-quality graphene sheets by an improved alternating current arc-discharge method. RSC Adv 2016;6(95):93119–24.
[19] Singh V, Jangou D, Zhai L, Das S, Khondaker SI, Seal S. Graphene based materials: past, present and future. Prog Mater Sci 2011;56(8):1178–271.
[20] Guler O, Guler SH, Selen V, Albayrak MG, Evin E. Production of graphene layer by liquid-phase exfoliation with low sonication power and sonication time from synthesized expanded graphite. Fuller Nanotub Car N 2016;24(2):123–7.
[21] Yang Y, Liu RL, Wu JY, Jiang XH, Cao P, Hu XF, et al. Bottom-up fabrication of graphene on silicon/silica substrate via a facile soft-hard template approach. Sci Rep 2015:5:13480.
[22] Yazdi GR, Iakimov T, Yakimova E. Epitaxial graphene on SiC: a review of growth and characterization. Crystals 2016;6(5):53.
[23] Dato A, Frenklach M. Substrate-free microwave synthesis of graphene: experimental conditions and hydrocarbon precursors. New J Phys 2010;12:125013.
[24] Jacobberger RM, Machhi R, Wroblewski J, Taylor B, Gillian-Daniel AL, Arnold MS. Simple graphene synthesis via chemical vapor deposition. J Chem Educ 2015;92(11):1903–7.
[25] Hou L, Shi YY, Jiang GX, Liu W, Han HL, Feng QH, et al. Smart nanocomposite hydrogels based on azo...
crosslinked graphene oxide for oral colon-specific drug delivery. Nanotechnology 2016;27(31):315105.

[26] Liu Z, Robinson JT, Sun XM, Dai HJ. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc 2008;130(33):10876–7.

[27] Tripathi SK, Goyal R, Gupta KC, Kumar P. Functionalized graphene oxide mediated nucleic acid delivery. Carbon 2013;51:224–35.

[28] Dou C, Ding N, Luo F, Hou TY, Cao Z, Bai Y, et al. Graphene-based microRNA transfection blocks preosteoclast fusion to increase bone formation and vascularization. Adv Sci 2018;5(2):1700578.

[29] Liu KP, Zhang JJ, Chen CPF, Zheng TT, Wang CM, Zhu JJ. Green and facile synthesis of highly biocompatible graphene nanosheets and its application for cellular imaging and drug delivery. J Mater Chem 2011;21(32):12034–40.

[30] Rana VK, Choi MC, Kong JY, Kim GY, Kim MJ, Kim SH, et al. Synthesis and drug-delivery behavior of chitosan-functionalized graphene oxide hybrid nanosheets. Macromol Mater Eng 2011;296(2):131–40.

[31] Lai WF, He ZD. Design and fabrication of hydrogel-based nanoparticulate systems for in vivo drug delivery. J Control Release 2016;243:269–82.

[32] Lai WF, Rogach AL. Hydrogel-based materials for delivery of herbal medicines. ACS Appl Mater Interfaces 2017;9(1):1150–20.

[33] Lai WF. Cyclodextrins in non-viral gene delivery. Biomaterials 2014;35(1):401–11.

[34] Lai WF. Microfluidic methods for non-viral gene delivery. Curr Gene Ther 2015;15(1):55–63.

[35] Lai WF, Lin MCM. Nucleic acid delivery with chitosan and its derivatives. J Control Release 2009;134(3):158–68.

[36] Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, et al. Renal clearance of quantum dots. Nat Biotechnol 2007;25(10):1165–70.

[37] Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008;69(1):1–9.

[38] Moghimi SM. Exploiting bone marrow microvascular structure for drug delivery and future therapies. Adv Drug Deliv Rev 1995;17(1):61–73.

[39] Nakao A, Tabata Y, Yamaoka T, Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J Control Release 1997;46(3):253–61.

[40] Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283–318.

[41] Banerjee T, Mitra S, Kumar Singh A, Kumar Sharma R, Maitra A. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 2002;243(1–2):93–105.

[42] Moghimi SM. Mechanisms of spleen clearance of blood cells and particles: towards development of new splenotropic agents. Adv Drug Deliv Rev 1995;17(1):103–15.

[43] Takakura Y, Mahato RI, Hashida M. Extravasation of macromolecules. Adv Drug Deliv Rev 1998;34(1):93–108.

[44] Sun XM, Liu Z, Welsher K, Robinson JT, Goodwin A, Zarin S, et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008;1(3):203–12.

[45] Kim J, Cote LJ, Kim F, Yuan W, Shull KR, Huang JX. Graphene oxide sheets at interfaces. J Am Chem Soc 2010;132(23):8180–6.

[46] Wang XL, Bai H, Shi GQ. Size fractionation of graphene oxide sheets by pH-assisted selective sedimentation. J Am Chem Soc 2011;133(16):6338–42.

[47] Ritter KA, Lyding JW. The influence of edge structure on the electronic properties of graphene quantum dots and nanoribbons. Nat Mater 2009;8(3):235–42.

[48] Ma L, Wang JL, Ding F. Strain-induced orientation-selective cutting of graphene into graphene nanoribbons on oxidation. Angew Chem Int Edit 2012;51(5):1161–4.

[49] Neubeck S, Ponomarenko LA, Freitag F, Giesbers AJM, Zeilter U, Morozov SV, et al. From one electron to one hole: quasiparticle counting in graphene quantum dots determined by electrochemical and plasma etching. Small 2010;6(14):1469–73.

[50] Pan DY, Zhang JC, Li Z, Wu MH. Hydrothermal route for cutting graphene sheets into blue-luminescent graphene quantum dots. Adv Mater 2010;22(6):734–8.

[51] Qian ZS, Zhou J, Chen JR, Wang C, Chen CC, Feng H. Nanosized N-doped graphene oxide with visible fluorescence in water for metal ion sensing. J Mater Chem 2011;21(44):17635–7.

[52] Herrmann S, Winter G, Mohs L, Siepmann F, Siepmann J. Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Control Release 2007;118(2):161–8.

[53] Zhou Y, Wu XY. Modeling and analysis of dispersed-drug release into a finite medium from sphere ensembles with a boundary layer. J Control Release 2003;90(1):23–36.

[54] Chen J, Kozlovskaia V, Goins A, Campos-Gomez J, Saeed M, Kharlamieva E. Biocompatible shaped particles from dried multilayer polymer capsules. Biomacromolecules 2013;14(11):3830–41.

[55] Shimonis O, Postama A, Yan Y, Scott AM, Heath JK, Nice EC, et al. Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting. ACS Nano 2012;6(2):1463–72.

[56] Ci L, Xu ZP, Wang LG, Gao W, Ding F, Kelly KF, et al. Controlled nanocutting of graphene. Nano Res 2008;1(2):116–22.

[57] Wu B, Geng D, Guo Y, Huang L, Xue Y, Zheng J, et al. Equiangular hexagon-shape-controlled synthesis of graphene on copper surface. Adv Mater 2011;23(31):3522–5.

[58] Kim S, Hwang SW, Kim MK, Shin DY, Shin DH, Kim CO, et al. Anomalous behaviors of visible luminescence from graphene quantum dots: interplay between size and shape. ACS Nano 2012;6(9):8203–8.

[59] Chen Y, Yang Y, Xian Y, Singh P, Feng J, Cui S, et al. Multifunctional graphene-oxide-reinforced dissolvable polymeric microneedles for transdermal drug delivery. ACS Appl Mater Interfaces 2020;12(1):352–60.

[60] Aderibigbe BA, Owonubi SJ, Jayaramudju J, Sadiku ER, Ray SS. Targeted drug delivery potential of hydrogel biocomposites containing partially and thermally reduced graphene oxide and natural polymers prepared via green process. Colloid Polym Sci 2015;293(2):409–20.

[61] Mahnaz S, Heidar R. Payload delivery of anticancer drug Tegafur with the assistance of graphene oxide nanosheet during biomembrane penetration: molecular dynamics simulation survey. Appl Surf Sci 2020;517:146186.

[62] Mahdavi M, Rahmani F, Nouranian S. Molecular simulation of pH-dependent diffusion, loading, and release of doxorubicin in graphene and graphene oxide drug delivery systems. J Mater Chem B 2016;4(46):7441–51.

[63] Hashemzadeh H, Raisi H. Understanding loading, diffusion and releasing of doxorubicin and paclitaxel dual delivery in graphene and graphene oxide carriers as highly efficient drug delivery systems. Appl Surf Sci 2020;500:144220.

[64] Raza K, Thotakura N, Kumar P, Joshi M, Bhushan S, Bhatai A, et al. C60-fullerenes for delivery of docetaxel to breast cancer cells: a promising approach for enhanced efficacy and better pharmacokinetic profile. Int J Pharmaceut 2015;495(1):551–9.
et al. Engineered redox-responsive PEG detachment mechanism in PEGylated nano-graphene oxide for intracellular drug delivery. Small 2012;8(5):760–9.

[81] Yang XY, Zhang XY, Ma YF, Huang Y, Wang YS, Chen YS. Superparamagnetic graphene oxide-Fe₃O₄ nanoparticles hybrid for controlled targeted drug carriers. J Mater Chem 2009;19(18):2710–14.

[82] Li XY, Huang XL, Liu DP, Wang X, Song SY, Zhou L, et al. Synthesis of 3D hierarchical Fe₃O₄/graphene composites with high lithium storage capacity and for controlled drug delivery. J Phys Chem C 2011;115(44):21567–72.

[83] Abdollahi Z, Taheri-Kafraei A, Bahrani SA, Kajani AA. PEGylated graphene oxide/superparamagnetic nanocomposite as a high-efficiency loading nanocarrier for controlled delivery of methotrexate. J Biotechnol 2019;298:88–97.

[84] Shen H, Liu M, He HX, Zhang LM, Huang J, Chong Y, et al. PEGylated graphene oxide-mediated protein delivery for cell function regulation. ACS Appl Mater Inter 2012;4(11):6317–23.

[85] La WG, Park S, Yoon HH, Jeong GJ, Lee TJ, Bang SH, et al. Delivery of a therapeutic protein for bone regeneration from a substrate coated with graphene oxide. Small 2013;9(23):4051–60.

[86] Lei HZ, Mi LJ, Zhou XJ, Chen JJ, Hu J, Guo SW, et al. Adsorption of double-stranded DNA to graphene oxide preventing enzymatic digestion. Nanoscale 2011;3(9):3888–92.

[87] Varghese N, Mogera U, Govindaraj A, Das A, Maiti PK, Sood AK, et al. Binding of DNA nucleobases and nucleosides with graphene. Chemphyschem 2009;10(1):206–10.

[88] Lu CH, Zhu CL, Li J, Liu JJ, Chen X, Yang HH. Using graphene to protect DNA from cleavage during cellular delivery. Chem Commun 2010;46(18):3116–18.

[89] Tang ZW, Wu H, Cort JR, Buchko GW, Zhang YY, Shao YY, et al. Constraint of DNA on functionalized graphene improves its biostability and specificity. Small 2010;6(11):1205–9.

[90] Kim H, Namgung R, Singh K, Oh IK, Kim WJ. Graphene oxide-polyethyleneimine nanoconductor as a gene delivery vector and bioimaging tool. Bioconjugate Chem 2011;22(12):2558–67.

[91] Lai WF. Nucleic acid therapy for lifespan prolongation: present and future. J Biosciences 2011;36(4):725–9.

[92] Lai WF. In vivo nucleic acid delivery with PEI and its derivatives: current status and perspectives. Expert Rev Med Devices. 2011;8(2):173–85.

[93] Lai WF. Nucleic acid delivery: roles in biogerontological interventions. Ageing Res Rev 2013;12(1):310–15.

[94] Lai WF, Jung HS. Cell transfection with a β-cyclodextrin-PEI-polyol,1,3,4-triol nanoparticle. PLoS One 2014;9(6):e100258.

[95] Lai WF, Lin MC. Folate-conjugated chitosan-poly(ethyleneimine) copolymer as an efficient and safe vector for gene delivery in cancer cells. Curr Gene Ther 2015;15(5):472–80.

[96] Chen BA, Liu M, Zhang LM, Huang J, Yao JL, Zhang ZJ. Polyethyleneimine-functionalized graphene oxide as an efficient gene delivery vector. J Mater Chem 2011;21(21):7736–41.

[97] Paul A, Hasan A, Al Kindi H, Gaharwar AK, Rao VTS, Nikkhah M, et al. Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano 2014;8(8):8050–62.

[98] Lv Y, Tao L, Blih SWA, Yang HH, Pan QX, Zhu LM. Targeted delivery and controlled release of doxorubicin into cancer
cells using a multifunctional graphene oxide. Mat Sci Eng C Mater Biol Appl 2016;59:652–60.

[99] Choi HY, Lee TJ, Yang GM, Oh J, Won J, Han J, et al. Efficient mRNA delivery with graphene oxide-polyethyleneimine for generation of footprint-free human induced pluripotent stem cells. J Control Release 2016;235:222–35.

[100] Zhou X, Laroche F, Lamers GEM, Torracca V, Vosskamp F, Lu T, et al. Ultra-small graphene oxide functionalized with polyethyleneimine (PEI) for very efficient gene delivery in cell and zebrafish embryos. Nano Res 2012;5(10):703–9.

[101] Dong HF, Ding L, Yan F, Ji RX, Ju HX. The use of polyethyleneimine-grafted graphene nanoribbon for cellular delivery of locked nucleic acid modified molecular beacon for recognition of microRNA. Biomaterials 2011;32(15):3875–82.

[102] Liu XH, Ma DM, Tang H, Tan L, Xie QJ, Zhang YY, et al. Polyamidoamine dendrimer and oleic acid-functionalized graphene as bio-compatible and efficient gene delivery vectors. ACS Appl Mater Interfaces 2014;6(11):8173–83.

[103] Zhang LM, Wang ZL, Lu ZX, Shen H, Huang J, Zhao QH, et al. PEGylated reduced graphene oxide as a superior ssRNA delivery system. J Mater Chem B 2013;1(6):749–55.

[104] Sun JL, Chao J, Huang J, Yin M, Zhang H, Peng C, et al. Uniform small graphene oxide as an efficient cellular nanocarrier for immunostimulatory CpG oligonucleotides. ACS Appl Mater Interfaces 2014;6(10):7926–32.

[105] Zhi F, Dong HF, Jia XF, Guo WJ, Lu HT, Yang YL, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS One 2013;8(3):e60034.

[106] Yang XC, Zhao NN, Xu FJ. Bioelavable graphene oxide based-nanohybrids synthesized via ATRP for gene/drug delivery. Nanoscale 2014;6(11):6141–50.

[107] Zhang HJ, Yan T, Xu S, Feng SN, Huang DD, Fujita M, et al. Graphene oxide-chitosan nanocomposites for intracellular delivery of immunostimulatory CpG oligodeoxynucleotides. Mat Sci Eng C Mater Biol Appl 2017;73:144–51.

[108] Dowidar M, Abdelhamid HN, Hallbrink M, Zou XD, Langlel U. Graphene oxide nanosheets in complex with cell penetrating peptides for oligonucleotides delivery. BBA-Gen Subjects 2017;1861(9):2344–41.

[109] Imani R, Emami SH, Faghihi S. Synthesis and characterization of an octaarginine functionalized graphene oxide nano-carrier for gene delivery applications. Phys Chem Chem Phys 2015;17(9):6328–39.

[110] Tian XY, Liu L. Drug discovery enters a new era with multi-target intervention strategy. Chin J Integr Med 2012;18(7):539–42.

[111] Lai WF, Rogach AL, Wong WT. One-pot synthesis of an emulsion-templated hydrogel-microsphere composite with tunable properties. Compos Part A-App S 2018;113:318–29.

[112] Lai WF, Sushe AS, Rogach AL, Wang GA, Huang MJ, Hu WJ, et al. Electrospray-mediated preparation of compositionally homogeneous core-shell hydrogel microparticles for sustained drug release. RSC Adv 2017;7(70):44482–91.

[113] Bao HQ, Pan YZ, Ping Y, Sahoo NG, Wu TF, Li L, et al. Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery. Small 2011;7(11):1569–78.

[114] Liu T, Li J, Wu X, Zhang S, Lu Z, Li G, et al. Transferfin-targeting redox hyperbranched poly(amido amine)-functionalized graphene oxide for sensitized chemotherapy combined with gene therapy for nasopharyngeal carcinoma. Drug Deliv 2019;26(1):744–55.

[115] Kim H, Lee D, Kim J, Kim TJ, Kim WJ. Photothermally triggered cytotoxic drug delivery via endosome disruption using a functionalized reduced graphene oxide. ACS Nano 2013;7(8):6735–46.

[116] Kim H, Kim WJ. Photothermally controlled gene delivery by reduced graphene oxide-polyethyleneimine nanocomposite. Small 2014;10(1):117–26.

[117] Lammel T, Boisseaux P, Fernandez-Cruz ML, Navas JM. Internalization and cytotoxicity of graphene oxide and carboxyl graphene nanoplatelets in the human hepatocellular carcinoma cell line Hep G2. Part Fibre Toxicol 2013;10:27.

[118] Xu Q, Leong J, Chua QY, Chi YT, Chow PK, Pack DW, et al. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 2013;34(21):5149–62.

[119] Wang XJ, Podila R, Shannahah JH, Rao AM, Brown JM. Intravenously delivered graphene nanosheets and multiwalled carbon nanotubes induce site-specific Th2 inflammatory responses via the IL-33/ST2 axis. Int J Nanomed 2013;8:1733–48.

[120] Chowdhury SM, Lallwani G, Zhang KV, Yang JY, Neville K, Sitharaman B. Cell specific cytotoxicity and uptake of graphene nanoribbons. Biomaterials 2013;34(1):283–93.

[121] Duch MC, Budinger GRS, Liang YT, Soberanes S, Urich D, Chiarella SE, et al. Minimizing oxidation and stable nanoscale dispersion improves the biocompatibility of graphene in the lung. Nano Lett 2011;11(12):5201–7.

[122] Song S, Shen H, Wang Y, Chu X, Xie J, Zhou N, et al. Biomedical application of graphene: from drug delivery, tumor therapy, to theranostics. Colloids Surf B Biointerfaces 2020;185:110596.

[123] Beyen AC, Gärtner K, van Zutphen LFM. Standardization of animal experimentation. Principles of laboratory animal science. van Zutphen LFM, Baumann V, Beyen AC, editors. Amsterdam: Elsevier; 2003.